FDA accepts Athenex application for oral paclitaxel for breast cancer

Under Priority Review status, the FDA has accepted Athenex’s (NASDAQ:ATNX) marketing application seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast cancer.

The agency’s action date is February 28, 2021.

https://seekingalpha.com/news/3610363-fda-accepts-athenex-application-for-oral-paclitaxel-for-breast-cancer